- Conditions
- Acute Migraine
- Interventions
- ZP-Zolmitriptan, Placebo
- Drug
- Lead sponsor
- Zosano Pharma Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 36
- States / cities
- Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine
- Interventions
- M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches), M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups), M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups, Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose
- Drug
- Lead sponsor
- Zosano Pharma Corporation
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Migraine
- Interventions
- M207 Microneedle System
- Drug
- Lead sponsor
- Zosano Pharma Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- Migraine
- Interventions
- A: M207 3.8mg, 30 min, upper arm, B: M207 3.8 mg, 30 min, thigh, C: M207 3.8 mg, 1 hr, upper arm, D:zolmitriptan nasal spray
- Drug
- Lead sponsor
- Zosano Pharma Corporation
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Cluster Headache
- Interventions
- C213 Microneedle System, Placebo
- Drug
- Lead sponsor
- Zosano Pharma Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • Santa Monica, California + 9 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- ZP-PTH, FORTEO
- Drug
- Lead sponsor
- Zosano Pharma Corporation
- Industry
- Eligibility
- 55 Years to 85 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Migraine
- Interventions
- Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
- Drug
- Lead sponsor
- Zosano Pharma Corporation
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas